Novartis AG (NOVNZ.XC)

Compare

95.45

-6.13

(-6.03%)

At close: March 11 at 4:19:58 PM GMT

Molecular Partners AG (MLLCF) (FY 2024) Earnings Call Highlights: Strategic Shifts and ...

Despite challenges with collaborations, Molecular Partners AG (MLLCF) maintains a strong cash position and advances its promising pipeline.

GuruFocus.com 3 days ago

MOLN.SW

NVS
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting

Shareholders approved 28th consecutive dividend increase to CHF 3.50 (+6.1%) per share for 2024, representing a 3.5% yield¹ Shareholders elected Giovanni Caforio as new member and Chair of the Board of Directors as well as Elizabeth McNally as new member of the Board of Directors. Joerg Reinhardt, Charles L. Sawyers and William T. Winters did not stand for re-electionShareholders approved all other proposals by the Board of Directors, including the reduction of share capital, the 2024 report on

GlobeNewswire 4 days ago

NVS

NVSEF
3 Top Cancer Biotechs to Keep An Eye On in 2025

If the cancer space appeals to you, it's time to consider stocks like Novartis, Exact Sciences and Monte Rosa.

Zacks 4 days ago

NVS

EXAS

GLUE
ITM targets US approval for radiopharmaceutical after Phase III readout

The company is planning an NDA submission for the neuroendocrine tumour-targeting ITM-11 later in 2025.

Pharmaceutical Technology 5 days ago

NVS

GLDAF
Novartis AG (NVS): Among the Best Undervalued Stocks to Invest In Now

We recently compiled a list of the 11 Best Undervalued Stocks to Invest in Now. In this article, we are going to take a look at where Novartis AG (NYSE:NVS) stands against the other undervalued stocks. How Will Tariffs Affect the Market? On March 5th, BBC reported that the US stock market had fallen after […]

Insider Monkey 6 days ago

NVS
Novartis Near Buy Point; Earns Near-Best Overall Rating

Novartis saw its IBD SmartSelect Composite Rating jump to 96 Wednesday, out of a best=possible 99. The new score indicates that shares of the company, which is No. 1 in its industry group, are now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria. Winning stocks often have a 95 or higher grade in the early stages of a new price run, so that's a good starting point when looking for the best stocks to buy and watch.

Investor's Business Daily 6 days ago

NVS

NVSEF
Novartis Earnings Surprised The Street; Still Going Strong

A Relative Strength Rating upgrade for Novartis shows improving technical performance. Will it continue?

Investor's Business Daily 7 days ago

NVS

NVSEF
Novartis Gets CHMP Opinion for Label Expansion of Fabhalta

The CHMP recommends granting a marketing authorization to NVS' Fabhalta for the treatment of adults with C3 glomerulopathy, an ultra-rare, progressive kidney disease with no currently approved treatment.

Zacks 8 days ago

NVS
3 Dividend Stocks That Are No-Brainer Buys Right Now

It can be difficult to decide which dividend stocks to buy. After all, more than 5,700 of them trade on U.S. stock exchanges. Here's why they picked Johnson & Johnson (NYSE: JNJ), Novartis (NYSE: NVS), and Pfizer (NYSE: PFE).

Motley Fool 10 days ago

JNJ

PFE

NVS
Q4 2024 PTC Therapeutics Inc Earnings Call

Q4 2024 PTC Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 11 days ago

PTCT

NVS
Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)

Two-year efficacy and safety data analyses from Phase III SUNSHINE and SUNRISE trials of continuous Cosentyx® (secukinumab) treatment in HS to be presentedNew analyses of 52-week data from Phase III REMIX pivotal trials of investigational remibrutinib, demonstrating impact in key clinical outcomes for patients with CSU also to be presentedRegulatory submissions for remibrutinib as a treatment for CSU on track for filing in 1H 2025 Basel, February 28, 2025 – Novartis announced today it will prese

GlobeNewswire 11 days ago

NVS

NVSEF
Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)

If approved, Fabhalta® will be the only medicine indicated to selectively target the underlying cause of C3G1, an ultra-rare, progressive kidney disease with no currently approved treatments2-5 Phase III data demonstrated clinically meaningful 35.1% proteinuria reduction6; also, a stabilization of estimated glomerular filtration rate (eGFR) – a key measure of kidney function – was observed6-8 C3G is typically diagnosed in young adults2-5; approximately half of patients progress to kidney failur

GlobeNewswire 11 days ago

NVS

NVSEF
PTC Therapeutics Inc (PTCT) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ...

PTC Therapeutics Inc (PTCT) surpasses revenue expectations, strengthens cash position, and prepares for multiple product launches in 2025.

GuruFocus.com 11 days ago

PTCT

NVS
Q4 2024 Schrodinger Inc Earnings Call

Q4 2024 Schrodinger Inc Earnings Call

Thomson Reuters StreetEvents 12 days ago

NVS

SDGR
Schrodinger Inc (SDGR) Q4 2024 Earnings Call Highlights: Strong Software Growth Amidst Revenue ...

Despite a decline in total revenue, Schrodinger Inc (SDGR) showcases robust software performance and strategic collaborations for future growth.

GuruFocus.com 12 days ago

SDGR

NVS
Court Dismisses Novartis Challenge To Medicare Drug Price Negotiation Program

A federal court rejected Novartis Pharmaceuticals’, a unit of Novartis AG (NYSE:NVS) legal challenge to the Medicare Drug Price Negotiation Program, ruling that the program does not violate constitutional protections against excessive fines, unlawful takings, or compelled speech. The court determined that pharmaceutical manufacturers are not legally required to participate in the program, and those that do must adhere to its terms. Also Read: Novartis To Beef Up Heart Disease Offering With $3 Bi

Benzinga 13 days ago

NVS
Update: Novartis Stockholder Sandoz to Reportedly Sell 26.5 Million Shares

(Updates with Novartis' response in the fifth paragraph.) Novartis (NVS) stockholder Sandoz Famil

PREMIUM
MT Newswires 13 days ago

NVS

GSC
Sandoz family to get $2.9 billion from offloading part of its Novartis stake

The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss pharma giant Novartis, the bookrunner on the deal said on Wednesday. Emasan AG sold 26.5 million shares at a price of 98.25 Swiss francs in an accelerated bookbuilt offering, Goldman Sachs said. According to LSEG data, the Sandoz family was the third biggest shareholder in Novartis with a stake of 4.1%.

Reuters 13 days ago

NVS
Sandoz Family Pares Novartis Stake With $2.9 Billion Sale

(Bloomberg) -- Novartis AG’s Sandoz family sold a roughly 1.2% stake in the Swiss pharmaceutical group for 2.6 billion Swiss francs ($2.9 billion).Most Read from BloombergNYC’s Congestion Pricing Pulls In $48.6 Million in First MonthThe Trump Administration Takes Aim at Transportation ResearchShelters Await Billions in Federal Money for Homelessness ProvidersNYC to Shut Migrant Center in Former Hotel as Crisis EasesNew York’s Congestion Pricing Plan Faces Another Legal ShowdownThe Sandoz Family

Bloomberg 13 days ago

NVS
Sector Update: Health Care Stocks Higher Late Afternoon

Health care stocks were rising late Tuesday afternoon, with the NYSE Health Care Index adding 0.8% a

PREMIUM
MT Newswires 14 days ago

LLY

NVS

Performance Overview

Return	NOVNZ.XC	MSCI WORLD
YTD	+11.56%	-2.60%
1-Year	+12.30%	0.00%
3-Year	+19.06%	+26.14%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Novartis AG (NOVNZ.XC)

Molecular Partners AG (MLLCF) (FY 2024) Earnings Call Highlights: Strategic Shifts and ...

Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting

3 Top Cancer Biotechs to Keep An Eye On in 2025

ITM targets US approval for radiopharmaceutical after Phase III readout

Novartis AG (NVS): Among the Best Undervalued Stocks to Invest In Now

Novartis Near Buy Point; Earns Near-Best Overall Rating

Novartis Earnings Surprised The Street; Still Going Strong

Novartis Gets CHMP Opinion for Label Expansion of Fabhalta

3 Dividend Stocks That Are No-Brainer Buys Right Now

Q4 2024 PTC Therapeutics Inc Earnings Call

Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)

Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)

PTC Therapeutics Inc (PTCT) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ...

Q4 2024 Schrodinger Inc Earnings Call

Schrodinger Inc (SDGR) Q4 2024 Earnings Call Highlights: Strong Software Growth Amidst Revenue ...

Court Dismisses Novartis Challenge To Medicare Drug Price Negotiation Program

Update: Novartis Stockholder Sandoz to Reportedly Sell 26.5 Million Shares

Sandoz family to get $2.9 billion from offloading part of its Novartis stake

Sandoz Family Pares Novartis Stake With $2.9 Billion Sale

Sector Update: Health Care Stocks Higher Late Afternoon

Performance Overview